Asuka Hirai-Yuki
Overview
Explore the profile of Asuka Hirai-Yuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsuda M, Hirai-Yuki A, Kotani O, Kataoka M, Zheng X, Yamane D, et al.
PLoS Pathog
. 2024 Mar;
20(3):e1012091.
PMID: 38478584
No antiviral drugs currently are available for treatment of infection by hepatitis A virus (HAV), a causative agent of acute hepatitis, a potentially life-threatening disease. Chemical screening of a small-compound...
2.
Sasaki-Tanaka R, Shibata T, Moriyama M, Kogure H, Hirai-Yuki A, Okamoto H, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298659
The hepatitis A virus (HAV) infection causes acute hepatitis. HAV also induces acute liver failure or acute-on-chronic liver failure; however, no potent anti-HAV drugs are currently available in clinical situations....
3.
Matsumoto M, Modliszewski J, Shinozaki K, Maezawa R, Perez V, Ishikawa Y, et al.
Nucleic Acids Res
. 2023 Apr;
51(9):4451-4466.
PMID: 37094077
Interferon regulatory factor 1 (IRF1) is a critical component of cell-intrinsic innate immunity that regulates both constitutive and induced antiviral defenses. Due to its short half-life, IRF1 function is generally...
4.
Shiota T, Matsuda M, Zheng X, Nagata N, Ishii K, Suzuki R, et al.
J Virol
. 2022 Nov;
96(23):e0149622.
PMID: 36354341
Although hepatitis A virus (HAV) is associated only with acute hepatitis in humans, HAV RNA persists within the liver for months following resolution of liver inflammation and cessation of fecal...
5.
Shi S, Zheng X, Suzuki R, Li Z, Shiota T, Wang J, et al.
Eur J Med Chem
. 2022 May;
238:114452.
PMID: 35597006
Two series of flavonoid hybrids, totaling 42 compounds, were designed, synthesized and evaluated to develop antiviral compounds effective against hepatitis A virus (HAV). A recombinant viral screening system revealed that...
6.
Sun L, Li Y, Misumi I, Gonzalez-Lopez O, Hensley L, Cullen J, et al.
PLoS Pathog
. 2021 Sep;
17(9):e1009960.
PMID: 34591933
HAV-infected Ifnar1-/- mice recapitulate many of the cardinal features of hepatitis A in humans, including serum alanine aminotransferase (ALT) elevation, hepatocellular apoptosis, and liver inflammation. Previous studies implicate MAVS-IRF3 signaling...
7.
Yamane D, Feng H, Rivera-Serrano E, Selitsky S, Hirai-Yuki A, Das A, et al.
Nat Microbiol
. 2019 Apr;
4(7):1096-1104.
PMID: 30988429
Current models of cell-intrinsic immunity to RNA viruses centre on virus-triggered inducible antiviral responses initiated by RIG-I-like receptors or Toll-like receptors that sense pathogen-associated molecular patterns, and signal downstream through...
8.
Hirai-Yuki A, Whitmire J, Joyce M, Tyrrell D, Lemon S
Cold Spring Harb Perspect Med
. 2018 Apr;
9(1).
PMID: 29661811
Mechanistic analyses of hepatitis A virus (HAV)-induced pathogenesis have long been thwarted by the lack of tractable small animal models that recapitulate disease observed in humans. Several approaches have shown...
9.
Das A, Hirai-Yuki A, Gonzalez-Lopez O, Rhein B, Moller-Tank S, Brouillette R, et al.
mBio
. 2017 Sep;
8(5).
PMID: 28874468
Receptor molecules play key roles in the cellular entry of picornaviruses, and TIM1 (HAVCR1) is widely accepted to be the receptor for hepatitis A virus (HAV), an unusual, hepatotropic human...
10.
Hirai-Yuki A, Hensley L, Whitmire J, Lemon S
mBio
. 2016 Dec;
7(6).
PMID: 27923925
Importance: HAV is a hepatotropic, fecally/orally transmitted picornavirus that can cause severe hepatitis in humans. Recent work reveals that it has an unusual life cycle. Virus is found in cell...